Founded in 1852 and with over 53,000 employees, Providence Health & Services is a 27 hospital, plus 100 other kinds of healthcare facilities, organization. In this session, you will learn how Dr. Marton lead Providence’s clinical transformation by learning from and applying the best available practices faster, and more effectively to achieve truly safe, high quality care with the least waste and expense in ALL parts of the system.
HSA 525 RANK Education for Service--hsa525rank.comclaric34
FOR MORE CLASSES VISIT
www.hsa525rank.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
Question 2This committee develops blood usage policies and procedures. It is responsible for monitoring transfusion services and reviewing indications for transfusions, blood ordering practices, each transfusion episode, and transfusion reactions. The committee reports its findings and recommendations
For more course tutorials visit
www.newtonhelp.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
Question 2This committee develops blood usage policies and procedures. It is responsible for monitoring transfusion services and reviewing indications for transfusions, blood ordering practices, each transfusion episode, and transfusion reactions. The committee reports its findings and recommendations to the medical staff executive committee.
HSA 525 RANK Become Exceptional--hsa525rank.comannebronte5
FOR MORE CLASSES VISIT
www.hsa525rank.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
FOR MORE CLASSES VISIT
www.hsa525rank.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
For more course tutorials visit
www.newtonhelp.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
Question 2This committee develops blood usage policies and procedures. It is responsible for monitoring transfusion services and reviewing indications for transfusions, blood ordering practices, each transfusion episode, and transfusion reactions. The committee reports its findings and recommendations to the medical staff executive committee.
For more classes visit
www.snaptutorial.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
Question 2This committee develops blood usage policies and procedures. It is responsible for monitoring
Founded in 1852 and with over 53,000 employees, Providence Health & Services is a 27 hospital, plus 100 other kinds of healthcare facilities, organization. In this session, you will learn how Dr. Marton lead Providence’s clinical transformation by learning from and applying the best available practices faster, and more effectively to achieve truly safe, high quality care with the least waste and expense in ALL parts of the system.
HSA 525 RANK Education for Service--hsa525rank.comclaric34
FOR MORE CLASSES VISIT
www.hsa525rank.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
Question 2This committee develops blood usage policies and procedures. It is responsible for monitoring transfusion services and reviewing indications for transfusions, blood ordering practices, each transfusion episode, and transfusion reactions. The committee reports its findings and recommendations
For more course tutorials visit
www.newtonhelp.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
Question 2This committee develops blood usage policies and procedures. It is responsible for monitoring transfusion services and reviewing indications for transfusions, blood ordering practices, each transfusion episode, and transfusion reactions. The committee reports its findings and recommendations to the medical staff executive committee.
HSA 525 RANK Become Exceptional--hsa525rank.comannebronte5
FOR MORE CLASSES VISIT
www.hsa525rank.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
FOR MORE CLASSES VISIT
www.hsa525rank.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
For more course tutorials visit
www.newtonhelp.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
Question 2This committee develops blood usage policies and procedures. It is responsible for monitoring transfusion services and reviewing indications for transfusions, blood ordering practices, each transfusion episode, and transfusion reactions. The committee reports its findings and recommendations to the medical staff executive committee.
For more classes visit
www.snaptutorial.com
Question 1 The committee responsible for developing and/or approving policies relating to the handling and administration of drugs
Question 2This committee develops blood usage policies and procedures. It is responsible for monitoring
The Department for Innovation, Universities & Skills (DIUS) is working to build a standards and conformity assessment infrastructure which meets the needs of UK industry, through a range of policy activities
and through their relations on behalf of Government with BSI and the United Kingdom Accreditation Service (UKAS).
This booklet has been developed to further DIUS’s objective of ensuring effective and increased Government involvement in BSI
technical committees.
It aims is to educate members of Government departments and agencies on their rewards, role and responsibilities
when operating within BSI British Standards technical committees.
This publication should be conceived within the remit and scope of BS 0, the overarching governance requirements for all committee members.
This is a simple and easy to follow powerpoint presentation I had completed for an ICT class at my college. Its purpose was to showcase a basic knowledge of a topic within our field of study, as well as, create a presentation with animation and transitions to prove understanding of how to optimize presentation effectiveness.
Introducing the Next-Gen Patient Safety OrganizationHealth Catalyst
Eliminating avoidable harm is a problem that we can and should solve. The journey to become highly reliable at producing meaningful and sustainable outcomes improvements requires organizations to maximize their investments in safety.
Safety improvements are the result of people, and process changes with data-driven insights as the underlying secret ingredient, but most PSOs are missing this tight integration between the three. Does your PSO?
View this webinar announcing the next generation Health Catalyst Patient Safety Organization (HC PSO) and learn why coupling it with the Health Catalyst Patient Safety Monitor™ Suite—built by patient safety experts for patient safety experts—is such an important differentiator. Leading in this product announcement are two experts in patient safety, Michael Barton and Elaine St. James. In this webinar they share the following:
- Importance of active safety surveillance and analysis to discover safety vulnerabilities that are often overlooked.
- Operational efficiency and organizational risk avoidance available by hosting together the safety analytics and HC PSO.
- Effective safety governance and application of safety best practices that will improve outcomes in a measurable, and sustainable way.
- Integration of analytics, and benchmarking from a health care Data Operating System (DOS).
Implementation of an active trigger surveillance tool into your existing system is just one step on your safety journey. Eliminating preventable harm requires commitment to change, organizational buy-in and a number of key components that will be discussed in this webinar. We hope that you will view the webinar.
The Department for Innovation, Universities & Skills (DIUS) is working to build a standards and conformity assessment infrastructure which meets the needs of UK industry, through a range of policy activities
and through their relations on behalf of Government with BSI and the United Kingdom Accreditation Service (UKAS).
This booklet has been developed to further DIUS’s objective of ensuring effective and increased Government involvement in BSI
technical committees.
It aims is to educate members of Government departments and agencies on their rewards, role and responsibilities
when operating within BSI British Standards technical committees.
This publication should be conceived within the remit and scope of BS 0, the overarching governance requirements for all committee members.
This is a simple and easy to follow powerpoint presentation I had completed for an ICT class at my college. Its purpose was to showcase a basic knowledge of a topic within our field of study, as well as, create a presentation with animation and transitions to prove understanding of how to optimize presentation effectiveness.
Introducing the Next-Gen Patient Safety OrganizationHealth Catalyst
Eliminating avoidable harm is a problem that we can and should solve. The journey to become highly reliable at producing meaningful and sustainable outcomes improvements requires organizations to maximize their investments in safety.
Safety improvements are the result of people, and process changes with data-driven insights as the underlying secret ingredient, but most PSOs are missing this tight integration between the three. Does your PSO?
View this webinar announcing the next generation Health Catalyst Patient Safety Organization (HC PSO) and learn why coupling it with the Health Catalyst Patient Safety Monitor™ Suite—built by patient safety experts for patient safety experts—is such an important differentiator. Leading in this product announcement are two experts in patient safety, Michael Barton and Elaine St. James. In this webinar they share the following:
- Importance of active safety surveillance and analysis to discover safety vulnerabilities that are often overlooked.
- Operational efficiency and organizational risk avoidance available by hosting together the safety analytics and HC PSO.
- Effective safety governance and application of safety best practices that will improve outcomes in a measurable, and sustainable way.
- Integration of analytics, and benchmarking from a health care Data Operating System (DOS).
Implementation of an active trigger surveillance tool into your existing system is just one step on your safety journey. Eliminating preventable harm requires commitment to change, organizational buy-in and a number of key components that will be discussed in this webinar. We hope that you will view the webinar.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
Prescient Therapeutics (PTX:ASX) is an ASX-listed biotechnology company focused on improving outcomes for cancer patients by developing personal medicines, using CAR-T and targeted therapy approaches.
Universal CAR-T therapies like OmniCAR have the potential to take personalised cancer treatment to the next level, by combining the cancer-killing capabilities of a T-cell with the control and pharmacology of a drug.
The medical sector's innovations drive ongoing change in the healthcare technology sector. From MRI scans and X-rays to robotic surgery and virtual reality, the healthcare industry is undergoing a significant digital shift. To get a report in detail, contact us at - info@insights10.com
Q2 2015 ARM - Alliance for Regenerative Medicine
Quarterly Data Report: Q2 2015 provides an in-depth look at regenerative medicine and advanced therapies sector trends and metrics compiled from more than 580 leading therapeutic companies worldwide.
Similar to Nordnetin aamiaistilaisuus 27.5.2015 (20)
”Investing in the future with megatrends and explore how you can invest susta...Nordnet Suomi
Megatrendit ovat ilmiöitä, jotka muuttavat yhteiskuntia ja talouksia ja samalla toimivat innovaation ja kehityksen ajureina yrityksille. Ne eivät vaikuta vain kulutus- ja asumistottumuksiimme, vaan ne muovaavat myös valtioiden politiikkaa ja yritysten strategioita.
Jotta sijoittaja voisi hyötyä näistä rakenteellisista muutoksista, ne tulee tunnistaa ajoissa. BlackRock näkee viisi megatrendiä, jotka tulevat erityisesti muovaamaan tulevaisuuttamme – sitä, miten elämme ja työskentelemme. Voit lukea lisää aiheesta tältä sivulta: https://www.nordnet.fi/fi/kampanjat/ishares?utm_campaign=ishares&utm_term=cm&utm_medium=social&utm_source=slideshare&utm_content=megatrends-etf-ishares-webcast
Jukka Oksaharjun esitys osakesäästötilistä: Vuosi 2020 – vähemmän osinkoveroh...Nordnet Suomi
Kuinka maksimoida osakesäästötilin hyöty? Miten valita osinko-osakkeet osakesäästötilille? Millainen on osinkojen uudelleensijoittamisen rooli varhaisessa riippumattoon nousemisessa?
Nordnetin osakestrategi Jukka Oksaharju puhui 19.9.2019 Sijoittaja 2019 -tapahtumassa aiheesta "Vuosi 2020 – vähemmän osinkoverohelvettiä" Katso taltiointi Nordnet Suomen YouTube-kanavalta!
Kolme tapaa rakentaa osakesäästötilisalkkuNordnet Suomi
Kuinka maksimoida osakesäästötilin hyöty? Millaisille sijoittajille osakesäästötili sopii?
Nordnetin maajohtaja Suvi Tuppurainen puhui 28.9.2019 Turun Talouspäivät -tapahtumassa aiheesta "Kolme tapaa rakentaa osakesäästötilisalkku".
Katso esityksen taltiointi Nordnet Suomen YouTube-kanavalta https://youtu.be/zmCmXbk1848
Lue lisää osakesäästötilistä: https://www.nordnet.fi/fi/palvelut/tilit/osakesaastotili?utm_campaign=osakesaastotili&utm_term=cm&utm_medium=social&utm_source=slideshare&utm_content=turuntalouspaivat
USDA Loans in California: A Comprehensive Overview.pptxmarketing367770
USDA Loans in California: A Comprehensive Overview
If you're dreaming of owning a home in California's rural or suburban areas, a USDA loan might be the perfect solution. The U.S. Department of Agriculture (USDA) offers these loans to help low-to-moderate-income individuals and families achieve homeownership.
Key Features of USDA Loans:
Zero Down Payment: USDA loans require no down payment, making homeownership more accessible.
Competitive Interest Rates: These loans often come with lower interest rates compared to conventional loans.
Flexible Credit Requirements: USDA loans have more lenient credit score requirements, helping those with less-than-perfect credit.
Guaranteed Loan Program: The USDA guarantees a portion of the loan, reducing risk for lenders and expanding borrowing options.
Eligibility Criteria:
Location: The property must be located in a USDA-designated rural or suburban area. Many areas in California qualify.
Income Limits: Applicants must meet income guidelines, which vary by region and household size.
Primary Residence: The home must be used as the borrower's primary residence.
Application Process:
Find a USDA-Approved Lender: Not all lenders offer USDA loans, so it's essential to choose one approved by the USDA.
Pre-Qualification: Determine your eligibility and the amount you can borrow.
Property Search: Look for properties in eligible rural or suburban areas.
Loan Application: Submit your application, including financial and personal information.
Processing and Approval: The lender and USDA will review your application. If approved, you can proceed to closing.
USDA loans are an excellent option for those looking to buy a home in California's rural and suburban areas. With no down payment and flexible requirements, these loans make homeownership more attainable for many families. Explore your eligibility today and take the first step toward owning your dream home.
2. Elemental Economics - Mineral demand.pdfNeal Brewster
After this second you should be able to: Explain the main determinants of demand for any mineral product, and their relative importance; recognise and explain how demand for any product is likely to change with economic activity; recognise and explain the roles of technology and relative prices in influencing demand; be able to explain the differences between the rates of growth of demand for different products.
how can I sell pi coins after successfully completing KYCDOT TECH
Pi coins is not launched yet in any exchange 💱 this means it's not swappable, the current pi displaying on coin market cap is the iou version of pi. And you can learn all about that on my previous post.
RIGHT NOW THE ONLY WAY you can sell pi coins is through verified pi merchants. A pi merchant is someone who buys pi coins and resell them to exchanges and crypto whales. Looking forward to hold massive quantities of pi coins before the mainnet launch.
This is because pi network is not doing any pre-sale or ico offerings, the only way to get my coins is from buying from miners. So a merchant facilitates the transactions between the miners and these exchanges holding pi.
I and my friends has sold more than 6000 pi coins successfully with this method. I will be happy to share the contact of my personal pi merchant. The one i trade with, if you have your own merchant you can trade with them. For those who are new.
Message: @Pi_vendor_247 on telegram.
I wouldn't advise you selling all percentage of the pi coins. Leave at least a before so its a win win during open mainnet. Have a nice day pioneers ♥️
#kyc #mainnet #picoins #pi #sellpi #piwallet
#pinetwork
Yes of course, you can easily start mining pi network coin today and sell to legit pi vendors in the United States.
Here the telegram contact of my personal vendor.
@Pi_vendor_247
#pi network #pi coins #legit #passive income
#US
What website can I sell pi coins securely.DOT TECH
Currently there are no website or exchange that allow buying or selling of pi coins..
But you can still easily sell pi coins, by reselling it to exchanges/crypto whales interested in holding thousands of pi coins before the mainnet launch.
Who is a pi merchant?
A pi merchant is someone who buys pi coins from miners and resell to these crypto whales and holders of pi..
This is because pi network is not doing any pre-sale. The only way exchanges can get pi is by buying from miners and pi merchants stands in between the miners and the exchanges.
How can I sell my pi coins?
Selling pi coins is really easy, but first you need to migrate to mainnet wallet before you can do that. I will leave the telegram contact of my personal pi merchant to trade with.
Tele-gram.
@Pi_vendor_247
How to get verified on Coinbase Account?_.docxBuy bitget
t's important to note that buying verified Coinbase accounts is not recommended and may violate Coinbase's terms of service. Instead of searching to "buy verified Coinbase accounts," follow the proper steps to verify your own account to ensure compliance and security.
The secret way to sell pi coins effortlessly.DOT TECH
Well as we all know pi isn't launched yet. But you can still sell your pi coins effortlessly because some whales in China are interested in holding massive pi coins. And they are willing to pay good money for it. If you are interested in selling I will leave a contact for you. Just telegram this number below. I sold about 3000 pi coins to him and he paid me immediately.
Telegram: @Pi_vendor_247
The European Unemployment Puzzle: implications from population agingGRAPE
We study the link between the evolving age structure of the working population and unemployment. We build a large new Keynesian OLG model with a realistic age structure, labor market frictions, sticky prices, and aggregate shocks. Once calibrated to the European economy, we quantify the extent to which demographic changes over the last three decades have contributed to the decline of the unemployment rate. Our findings yield important implications for the future evolution of unemployment given the anticipated further aging of the working population in Europe. We also quantify the implications for optimal monetary policy: lowering inflation volatility becomes less costly in terms of GDP and unemployment volatility, which hints that optimal monetary policy may be more hawkish in an aging society. Finally, our results also propose a partial reversal of the European-US unemployment puzzle due to the fact that the share of young workers is expected to remain robust in the US.
What price will pi network be listed on exchangesDOT TECH
The rate at which pi will be listed is practically unknown. But due to speculations surrounding it the predicted rate is tends to be from 30$ — 50$.
So if you are interested in selling your pi network coins at a high rate tho. Or you can't wait till the mainnet launch in 2026. You can easily trade your pi coins with a merchant.
A merchant is someone who buys pi coins from miners and resell them to Investors looking forward to hold massive quantities till mainnet launch.
I will leave the telegram contact of my personal pi vendor to trade with.
@Pi_vendor_247
how to swap pi coins to foreign currency withdrawable.DOT TECH
As of my last update, Pi is still in the testing phase and is not tradable on any exchanges.
However, Pi Network has announced plans to launch its Testnet and Mainnet in the future, which may include listing Pi on exchanges.
The current method for selling pi coins involves exchanging them with a pi vendor who purchases pi coins for investment reasons.
If you want to sell your pi coins, reach out to a pi vendor and sell them to anyone looking to sell pi coins from any country around the globe.
Below is the contact information for my personal pi vendor.
Telegram: @Pi_vendor_247
How Does CRISIL Evaluate Lenders in India for Credit RatingsShaheen Kumar
CRISIL evaluates lenders in India by analyzing financial performance, loan portfolio quality, risk management practices, capital adequacy, market position, and adherence to regulatory requirements. This comprehensive assessment ensures a thorough evaluation of creditworthiness and financial strength. Each criterion is meticulously examined to provide credible and reliable ratings.
How Does CRISIL Evaluate Lenders in India for Credit Ratings
Nordnetin aamiaistilaisuus 27.5.2015
1. Targeting a paradigm shift in stroke
rehabilitation
Janne Huhtala | CEO | Nexstim
Nordnet Investor Seminar, 27 May 2015 @NexstimOyj
2. 2
Importantinformation
This document and the information contained herein are being presented by Nexstim Oyj
(“Nexstim” or the “Company”). In connection with any presentation or review of this
document, you agree to be bound by the following limitations and notifications.
This document and the information contained herein are being provided to you solely for
your information. The distribution of this document in some jurisdictions may be restricted
by law and persons into whose possession this document comes are required to inform
themselves about and observe any such restrictions. Accordingly, this document may not be
distributed in any jurisdiction except under circumstances that will result in compliance with
applicable laws and regulations.
This document is not a prospectus, and the information contained herein does not and is not
intended to constitute an offer to sell or the solicitation of an offer to buy, nor shall there be
any sale of any securities referred to herein in any jurisdiction. This document and the
information contained herein are not an offer of securities in the United States and are not
for distribution in the United States. Any securities to which these materials relate have not
been and will not be, registered under the U.S. Securities Act 1933, as amended (the
"Securities Act") or with any securities regulatory authority of any state of the United States.
Any securities to which these materials relate may not be offered, sold, pledged or
otherwise transferred directly or indirectly within the United States or to, or for the account
or benefit of, U.S. Persons (as defined in Regulation S under the Securities Act).
Should any recipient of this document consider an investment in the Company, such
recipient must rely on their own examination of the legal, taxation, financial and other
consequences of any possible holding or transaction involving the Company’s shares,
including the merits and risks involved. Recipients should not treat the contents of the
document as advice relating to legal, taxation or other matters and are advised to consult
their own professional advisors concerning the acquisition, holding or disposal of shares in
the Company. This presentation does not purport to be all-inclusive or to contain any or all
the information that prospective investors may desire in analysing and deciding whether or
not to hold or transact in the Company’s shares.
Nexstim's NBS System is cleared by the FDA for assessment of the motor and speech cortices
for pre-procedural planning. The NBT System is not cleared for commercial distribution in
the United States.
FORWARD-LOOKING STATEMENTS
This document may contain forward-looking statements that reflect the Company’s current
views with respect to certain future events and potential financial performance. Although
the Company believes that the expectations reflected in such forward-looking statements
are reasonable, no assurance can be given that such expectations will materialise.
Accordingly, results could differ materially from those set out in the forward-looking
statements as a result of various factors. To the extent that this document contains opinions,
estimates, forecasts or other forward looking statements, no guarantees or undertakings
that these are correct or complete are given by the Company or any of its respective
members, advisors, officers or employees or any other person. Forecasts and assumptions
which are subject to economic and competitive uncertainty are outside such person’s
control and no guarantee can be given that projected results will be achieved or that
outcomes will correspond with forecasts. Information in this document may be changed,
added to or corrected without advance notification.
3. 3
Introduction toNexstim
Targeted
growth in
US and
Europe
Ongoing
pivotal Phase
III study in
stroke
rehabilitation
Strong
balance
sheet and
margins
Significant
unmet need
in post acute
stroke
rehabilitation
Experienced
management
team
Novel medtech company with strong position in brain navigation technology and software
Strong IP
CE mark &
FDA
clearance for
e-field based
navigation
4. 4
2014 Highlights
Q1
Q2Q3
Q4
2014 Highlights
Stroke Rehabilitation Phase II
Data published in International
Stroke Conference
Pivotal Phase III, NICHE Trial,
Started in 12 US Rehabilitation
sites – on track with interim
analysis in Q3 2015
NBS 5 release; the latest
generation of e-Field based
navigation software
and hardware
IPO Dual listing of Nexstim
Shares in Nasdaq First North in
Helsinki and Stockholm
6. 6
NexstimPositioned within StrokeCare Path
Acute
care
Stabilization and
spontaneous recovery
Post-acute rehab,
chronic patients
Early rehab and normal healing
process
40-60% will have motor
impairment after 90 days of the
stroke
Nexstim data suggest that plateau
of the recovery can be raised
higher than previously expected
and results can be reached post
normal spontaneous recovery.
Rehabilitation resources should be
allocated post this phase, but,
before patients get chronic, to
have continuous patient flow for
effective therapy
Acute care to
prevent the
damage
90 % of the
patients survive
Annual rehabilitation therapy,
inpatient or outpatient
Better 1st year therapy
response potentially lowers
the long term need for
therapy and support
Broken care path
NBT®
Days 0-10 Days 10-90 3-12 months from stroke 12 months onwards
Currently, patients are discharged from
acute care but with limited follow up
and rehabilitation until 12m from
stroke.
This gap in the care path doesn’t allow
effective continuous care to maximize
the efficacy of resources and funds
Nexstim’s solution is NBT® paired with
occupational therapy, in an outpatient
setting, to improve rehabilitation
outcome and lower the need for long
term care
7. Nexstim’s Navigated Brain Therapy® (NBT)
solution for stroke rehabilitation
7
Nexstim– Targetinga paradigm shift in stroke rehabilitation
Targeting a blockbuster market
Potentiaal game-changer technology
2.1 million strokes each year in US and Europe
712,000 patients is Nexstim’s target # of patients
$1.8 billion market potential for Nexstim
Few effective alternatives…
…still $8.5bn currently spent on stroke rehab in the US
Promising efficacy demonstrated in completed Phase
II clinical trial
Technology already validated – Pioneered the
technology to map motor and speech centers, with
120 devices installed worldwide and FDA clearance –
same technology now applied in stroke rehabilitation
Huge unmet need and commercial opportunity
Targeting a blockbuster market…
(market for post-acute stroke treatment)
…with a potential game-changer technology
Nexstim’s Navigated Brain Therapy® solution
for stroke rehabilitation
8. 8
NBT® for strokerehabilitation– How it works
Using a patient’s own MRI scan as a guide, Nexstim
provides precisely targeted, personalized,
magnetic stimulation to temporarily inhibit the
healthy side of the brain, normalising the balance
between the hemispheres.
Because the injured side is no longer dominated by
the healthy side of the brain, it is more responsive
to the physiotherapy. This results in limb
movement being potentially restored more quickly
to better functionality.
Validated e-Field Navigation gives Competitive Edge
9. 9
Efficacydemonstratedin Phase II trial
Note: “Robotics”, “Intentive conventional rehab” and “Non-navigated rTMS” data come from different studies. While not directly comparable, included in the above chart for illustrative purposes. | (1) Data for
“Treatment group” and “Sham group” from Nexstim Phase II clinical trial (Harvey et al, 2013) – per protocol figures. | (2) Data for “Robotics” and “Intensive conventional rehab” from published multi-center
trial (Lo et al, NEJM 2010) | (3) Data for “Non-navigated rTMS” from published multi-center trial (Kakuda et al, J Neuroeng Rehab 2012), 6 month follow-up not done. Responder rate = % of group that had
improvements above the 5 point minimal clinically important difference threshold.
0
5
10
15
20
Baseline 1 month
post treatment
6 months
post treatment
Nexstim NBT® group¹ Sham (placebo) group¹
Robotics² Intensive conventional rehab²
Non-navigated rTMS³ Min clinically important difference, MCID
Change in upper extremity Fugl-Meyer score from baseline
Difference: treatment
and sham groups
Absolute average improvement of
13.8 Fugl-Meyer scores
= difference of "holding an object"
and "buttoning a shirt"
Pre Post
Trial outcome:
The Phase II clinical trial in brief:
– Single centre at Rehabilitation Institute of Chicago (#1
rehabilitation hospital in US for 24 consecutive years)
– 29 patients of which 19 (10) in treatment (sham) group
– End-point = 6 months post treatment
P<0.05
84% responder rate
(above "MCID" for NBT® group)
10. 10
Nexstim’sunique technologyprovides distinct benefits
IntegrationofTMSandnavigation
● TMS-navigation integration
● Navigation is the key differentiator
● Improved accuracy
● Dosing precision
● Repeatability
● Non-invasive procedure
EnhancedlimbmoveSeveraldistinctbenefits
● Substantially
improved hand
movement after
treatment
demonstrated in
Nexstim’s Phase II trial
11. 11
Highlightsin StrokeRehabilitation(NBT®)
– 2.1m strokes each year in the US and Europe
– Stroke is the leading cause of long-term disability in Western worldHuge unmet need
Few effective alternatives
Promising, validated technology
Potential blockbuster market
Clear execution strategy
– While current standard treatment of physical/occupational therapy is not very
effective, $8.5bn is still currently spent on stroke rehab in the US
– $1.8bn is estimated value of Nexstim’s target market (US and Europe)
– Statistically significant efficacy in stroke rehabilitation vs. sham treatment
(standard therapy)
– Navigation already validated by NBS
– Phase III trial on track: Establish efficacy in Phase III to obtain FDA clearance and
KOL support
– Commercialisation strategy: Convince users of benefits, providers of economic
benefits and obtain reimbursement coverage from payers
13. 13
Phase III trials - Laying the groundworkfor commercialisation
Studyinbrief Conductedat12topUSrehabsites
Outcome data
FDA clearance
KOL support
● Document
effects/efficacy of
NBT on upper-limb
motor rehab
● Obtain FDA De
Novo 510(k)
clearance for right
to market and sell
NBT® in US
● Build support from
key opinion leaders
(KOLs) to support
commersialisation
● Establish clinical efficacy
of NBT® in upper-limb
motor rehabilitation
● Up to 198 patients
● 12 top US rehab sites –
RIC is central site (#1 US
rehabilitation hospital for
24 years)
● Dr. Richard L. Harvey lead
investigator – one of the
top experts in the field
● FDA reviewed protocol
Studygoals
Rehabilitation Institute of Chicago (central site)
TIRR Memorial Hermann Hospital (Houston)
Spaulding Rehabilitation Hospital (Boston)
Ohio State University (Columbus, OH)
Rancho Los Amigos National Rehabilitation Center
Burke Rehabilitation Hospital (White Plains, NY)
Duke University Medical Center (Durham, NC)
Columbia Cornell New York Presbyterian Hospital
Shepherd Center (Atlanta)
University of Cincinnati
Indiana University Indianapolis
Mayo Clinic (Phoenix, AZ)
14. 14
Statusof Clinical Development
SimplifiedtimelinePhaseIIImulti-centrestroketherapytrial
– Study initiated
Promising
results from
Phase II trial
Commer-
cialisation
May ‘15 Q3 ‘15 Q1 ‘16 Q3 ‘16
– Centres selected
– Enrolment on
schedule
Initiation On track Milestone 1 Milestone 2 Milestone 3
– Interim analysis
based on 81 patients
– Interim analysis
based on 138
patients
– Final analysis based
on 198 patients
Spring ‘14
● The clinical Phase III multi-center trial is progressing according to plans. The next
interim analysis milestones are estimated to be reached Q3 2015 and Q1 2016 and the
clinical evidence is assumed to be ready by the end of 2016
● In addition, chronic neuropathic pain trial in co-operation with The Walton Centre is
progressing according to plans
Progressing as Planned
15. 15
IP position
62 granted patents
69 pending patents
Right to software: Nexstim owns rights to its
NBT® and NBS Systems’ software developed in-
house.
Creating hurdles for competitors: e.g. by seeking
patent protection on different parts of the
products and making it more difficult for
potential competitors to create competing
products
Core algorithms kept as trade secrets: Not
patenting the core algorithms to avoid publicity
and loss of trade secrets
16. 16
Financials
EUR in thousands
H2 2014
6 months
H2 2013
6 months
FY 2014
12 months
FY 2013
12 months
Net sales 1,796.5 1,371.7 2,210.4 1,871.0
Profit/ -Loss for the period -5,318.1 -1,966.7 -10,445.4 -4,514.9
Cash flows from operating activities -5,277.1 -2,124.5 -7,785.2 -3,983.7
Cash in hand and at banks 11,483.7 1,010.0 11,483.7 1,010.0
Total equity 8,589.9 -2,382.1 8,589.9 -2,382.1
Equity ratio (%) 65.29 -30.23 65.29 -30.23
Revenue growth
from device sales
with CAPEX
business model
Improved cash
position from IPO
17. 17
Summaryand Outlook
● World-leading medical technology and software with game changing potential in
stroke rehabilitation
● Good progress since IPO – business on track
● Based on its business forecast and sensitivity analysis the company expects its net
sales from the sale of NBS Systems (Pre-Surgical Mapping, PSM) to grow during
financial year 2015 and operating profit to be positive during second half of the
financial year 2017 at the earliest
Targeting a Paradigm Shift in Stroke Rehabilitation